Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer

Research output: Contribution to journalReview articlepeer-review

Abstract

Metastatic prostate cancer continues to kill approximately 30,000 men per year. Since 2010, five new therapeutic agents have been Food and Drug Administration (FDA) approved to treat metastatic castration-resistant prostate cancer (mCRPC). With the increasing number of therapies available to clinicians, the most effective sequence in which to implement these treatments remains unknown. The presence or absence of symptoms (i.e., bony pain, visceral crisis) is a key parameter that informs the decision-making process regarding therapy. Treatment algorithms based on: 1) asymptomatic/minimal symptoms, 2) moderate symptoms or chemotherapy ineligible or 3) symptomatic disease need to be developed.

Original languageEnglish (US)
Pages (from-to)936-938
Number of pages3
JournalAsian Journal of Andrology
Volume17
Issue number6
DOIs
StatePublished - Nov 1 2015

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer'. Together they form a unique fingerprint.

Cite this